Collectively, the helix H3 mutations of PPARγ LBD found in various cancers disrupt the sophisticated ligand-binding systems of PPARγ, induce abnormal regulation of PPARγ transactivation and thus may affect tumor development or progression as loss-of-function mutations of PPARγ. The gene discussed is PPARG; the disease is neoplasm.